Literature DB >> 10545478

The MHC class II ligand lymphocyte activation gene-3 is co-distributed with CD8 and CD3-TCR molecules after their engagement by mAb or peptide-MHC class I complexes.

S Hannier1, F Triebel.   

Abstract

Previous studies indicated that signaling through lymphocyte activation gene-3 (LAG-3), a MHC class II ligand, induced by multivalent anti-receptor antibodies led to unresponsiveness to TCR stimulation. Here, lateral distribution of the LAG-3 molecules and its topological relationship (mutual proximity) to the TCR, CD8, CD4, and MHC class I and II molecules were studied in the plasma membrane of activated human T cells in co-capping experiments and conventional fluorescence microscopy. Following TCR engagement by either TCR-specific mAb or MHC-peptide complex recognition in T-B cell conjugates, LAG-3 was found to be specifically associated with the CD3-TCR complex. Similarly, following CD8 engagement LAG-3 and CD8 were co-distributed on the cell surface while only a low percentage of CD4-capped cells displayed LAG-3 co-caps. In addition, LAG-3 was found to be associated with MHC class II (i.e. DR, DP and DQ) and partially with MHC class I molecules. The supramolecular assemblies described here between LAG-3, CD3, CD8 and MHC class II molecules may result from an organization in raft microdomains, a phenomenon known to regulate early events of T cell activation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10545478     DOI: 10.1093/intimm/11.11.1745

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  26 in total

1.  CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells.

Authors:  Yongping Zhang; Xingying Zhang; Chen Cheng; Wei Mu; Xiaojuan Liu; Na Li; Xiaofei Wei; Xiang Liu; Changqing Xia; Haoyi Wang
Journal:  Front Med       Date:  2017-06-17       Impact factor: 4.592

2.  The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells.

Authors:  Laëtitia Maçon-Lemaître; Frédéric Triebel
Journal:  Immunology       Date:  2005-06       Impact factor: 7.397

3.  Lymphocyte activation gene 3 and coronary artery disease.

Authors:  Diana Golden; Antonina Kolmakova; Sunitha Sura; Anthony T Vella; Ani Manichaikul; Xin-Qun Wang; Suzette J Bielinski; Kent D Taylor; Yii-Der Ida Chen; Stephen S Rich; Annabelle Rodriguez
Journal:  JCI Insight       Date:  2016-10-20

Review 4.  LAG-3 in Cancer Immunotherapy.

Authors:  Monica V Goldberg; Charles G Drake
Journal:  Curr Top Microbiol Immunol       Date:  2011       Impact factor: 4.291

Review 5.  LAG3 (CD223) as a cancer immunotherapy target.

Authors:  Lawrence P Andrews; Ariel E Marciscano; Charles G Drake; Dario A A Vignali
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

6.  LAG-3 Confers a Competitive Disadvantage upon Antiviral CD8+ T Cell Responses.

Authors:  Kevin D Cook; Jason K Whitmire
Journal:  J Immunol       Date:  2016-05-20       Impact factor: 5.422

7.  Lymphocyte activation gene-3 expression defines a discrete subset of HIV-specific CD8+ T cells that is associated with lower viral load.

Authors:  José Peña; Norman G Jones; Stephanie Bousheri; David R Bangsberg; Huyen Cao
Journal:  AIDS Res Hum Retroviruses       Date:  2013-11-26       Impact factor: 2.205

8.  Characterization of LAG-3, CTLA-4, and CD8+ TIL density and their joint influence on the prognosis of patients with esophageal squamous cell carcinoma.

Authors:  Wenjia Wang; Donglai Chen; Yuhuan Zhao; Ting Zhao; Junmiao Wen; Yiming Mao; Chang Chen; Yonghua Sang; Yongsheng Zhang; Yongbing Chen
Journal:  Ann Transl Med       Date:  2019-12

Review 9.  Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy.

Authors:  Anna Śledzińska; Laurie Menger; Katharina Bergerhoff; Karl S Peggs; Sergio A Quezada
Journal:  Mol Oncol       Date:  2015-10-26       Impact factor: 6.603

10.  Molecular characterization of HLA class II binding to the LAG-3 T cell co-inhibitory receptor.

Authors:  Bruce J MacLachlan; Georgina H Mason; Alexander Greenshields-Watson; Frederic Triebel; Awen Gallimore; David K Cole; Andrew Godkin
Journal:  Eur J Immunol       Date:  2020-10-09       Impact factor: 6.688

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.